IP Library › Assignment 049246/0720
Patent Assignment
Reel/Frame 049246/0720

Confirmatory Assignment

Recorded: 2019-05-21 Pages: 22
Assignor
NOVARTIS AG
Executed: 2019-05-15
Assignee
SECURA BIO, INC.
1887 WHITNEY MESA DRIVE #1050, HENDERSON, NEVADA, 89014
Covered Properties (31)
Deacetylase Inhibitors
Patent: 6,552,065 →
Application: 09/944,275 →
Publication: US 2003/0018062
Deacetylase Inhibitors
Patent: 6,833,384 →
Application: 10/299,518 →
Publication: US 2004/0024067
Deacetylase Inhibitors
Patent: 7,067,551 →
Application: 10/984,501 →
Publication: US 2005/0085507
Deacetylase inhibitors
Application: 11/408,129 →
Publication: US 2006/0189674
Use of Hdac Inhibitors for the Treatment of Myeloma
Application: 11/996,323 →
Publication: US 2008/0221126
Deacetylase Inhibitors
Application: 12/045,885 →
Publication: US 2008/0176849
Polymorphs of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Patent: 7,989,494 →
Application: 12/302,564 →
Publication: US 2009/0192210
Salts of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Application: 12/302,571 →
Publication: US 2009/0197936
Process for Making N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide and Starting Materials Therefor
Application: 12/302,572 →
Publication: US 2009/0306405
Process for Making Salts of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Patent: 7,989,639 →
Application: 12/302,576 →
Publication: US 2009/0187029
Use of HDAC Inhibitors for the Treatment of Bone Destruction
Application: 12/601,538 →
Publication: US 2010/0179208
Use of Hdac Inhibitors for the Treatment of Myeloma
Patent: 8,883,842 →
Application: 12/717,373 →
Publication: US 2010/0160257
Salts of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Application: 12/775,001 →
Publication: US 2010/0286409
Salts of N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
Application: 13/006,485 →
Publication: US 2011/0112308
Use of Hdac Inhibitors for the Treatment of Bone Destruction
Application: 13/195,897 →
Publication: US 2012/0029047
Process for Making N-Hydroxy-3[4-[[[2-(2methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide and Starting Materials Therefor
Patent: 8,536,346 →
Application: 13/243,001 →
Publication: US 2012/0010418
Panobinostat Dosages for Multiple Myeloma
Application: 15/551,768 →
Publication: US 2018/0028497
Panobinostat Dosages for Multiple Myeloma
Application: 16/227,893 →
Publication: US 2019/0117622
Deacetylase inhibitors
Application: 60/229,943 →
Deacetylase inhibitors
Application: 60/292,232 →
Deacetylase inhibitors
Application: 60/307,490 →
Use of HDAC inhibitors for the treatment of myeloma
Application: 60/705,226 →
Polymorphs of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Application: 60/804,517 →
Salts of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Application: 60/804,523 →
Process for Making N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide and Starting Material Therefor
Application: 60/804,527 →
Process for Making Salts of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Application: 60/804,529 →
Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
Application: 60/853,259 →
Process for Making N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide and Starting Material Therefore
Application: 60/867,878 →
Salts of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Application: 60/869,993 →
Polymorphs of N-Hydroxy-3-[4-[[[2-(2-Methyl-1H-Indol-3-Yl)Ethyl]Amino]Methyl]Phenyl]-2E-2-Propenamide
Application: 60/883,224 →
Use of Hdac Inhibitors for the Treatment of Bone Destruction
Application: 60/940,735 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Feb 10, 2003
From: REMISZEWSKI, STACY WILLIAM; BAIR, KENNETH WALTER; VERSACE, RICHARD WILLIAM; PEREZ, LAWRENCE BLAS
To: NOVARTIS AG
Reel/Frame 013753/0990 →
Assignment of Assignor's Interest Apr 8, 2011
From: BAJWA, JOGINDER; PARKER, DAVID JOHN; SLADE, JOEL
To: NOVARTIS AG
Reel/Frame 026096/0710 →
Assignment of Assignor's Interest May 20, 2011
From: ACEMOGLU, MURAT; BAJWA, JOGINDER S.; KARPINSKI, PIOTR; PAPOUTSAKIS, DIMITRIS
To: NOVARTIS AG
Reel/Frame 026316/0103 →
Assignment of Assignor's Interest May 24, 2013
From: ACEMOGLU, MURAT; BAJWA, JOGINDER S.; PARKER, DAVID JOHN; SLADE, JOEL
To: NOVARTIS AG
Reel/Frame 030482/0210 →
Assignment of Assignor's Interest Aug 25, 2014
From: ATADJA, PETER W.
To: NOVARTIS AG
Reel/Frame 033602/0503 →
Assignment of Assignor's Interest Apr 17, 2015
From: REMISZEWSKI, STACY WILLIAM; BAIR, KENNETH WALTER; VERSACE, RICHARD WILLIAM; PEREZ, LAWRENCE BLAS
To: NOVARTIS AG
Reel/Frame 035434/0693 →
Assignment of Assignor's Interest Aug 24, 2017
From: BINLICH, FLORENCE
To: NOVARTIS PHARMA S.A.S.
Reel/Frame 043382/0050 →
Assignment of Assignor's Interest Aug 24, 2017
From: LIN, RONG; MU, SONG; PAUL, SOFIA
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 043382/0105 →
Assignment of Assignor's Interest Aug 24, 2017
From: NOVARTIS PHARMA S.A.S.
To: NOVARTIS AG
Reel/Frame 043382/0191 →
Assignment of Assignor's Interest Aug 24, 2017
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 043382/0209 →
Assignment of Assignor's Interest Aug 24, 2017
From: NOVARTIS PHARMACEUTICALS CORPORATION
To: NOVARTIS AG
Reel/Frame 043382/0220 →
Assignment of Assignor's Interest Aug 24, 2017
From: GRAZIOLI, LAURA; CAPDEVILLE, RENAUD
To: NOVARTIS PHARMA AG
Reel/Frame 043382/0065 →
Assignment of Assignor's Interest Mar 1, 2019
From: NOVARTIS PHARMA AG
To: SECURA BIO, INC.
Reel/Frame 048477/0661 →
Security Interest Mar 5, 2019
From: SECURA BIO, INC.
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 048510/0364 →
Assignment of Assignor's Interest May 30, 2019
From: NOVARTIS PHARMACEUTICALS CORPORATION
To: NOVARTIS AG
Reel/Frame 049322/0549 →
Assignment of Assignor's Interest May 30, 2019
From: REMISZEWSKI, STACY WILLIAM; BAIR, KENNETH WALTER; VERSACE, RICHARD WILLIAM; PEREZ, LAWRENCE BLAS
To: NOVARTIS AG
Reel/Frame 049321/0949 →
Assignment of Assignor's Interest May 30, 2019
From: GRAZIOLI, LAURA; CAPDEVILLE, RENAUD
To: NOVARTIS PHARMA AG
Reel/Frame 049322/0128 →
Assignment of Assignor's Interest May 30, 2019
From: BINLICH, FLORENCE
To: NOVARTIS PHARMA S.A.S.
Reel/Frame 049322/0213 →
Assignment of Assignor's Interest May 30, 2019
From: LIN, RONG; MU, SONG; PAUL, SOFIA
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 049322/0345 →
Assignment of Assignor's Interest May 30, 2019
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 049322/0402 →
Assignment of Assignor's Interest May 30, 2019
From: NOVARTIS PHARMA S.A.S.
To: NOVARTIS AG
Reel/Frame 049322/0439 →
Release of Ip Security Interest at Reel/Frame 048510/0364 Oct 31, 2022
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: SECURA BIO, INC.
Reel/Frame 061814/0821 →
Assignment of Assignor's Interest Feb 27, 2023
From: SECURA BIO, INC.
To: PHARMA& SCHWEIZ GMBH
Reel/Frame 062872/0533 →
Assignment of Assignor's Interest Jun 15, 2023
From: SECURA BIO, INC.
To: PHARMA& SCHWEIZ GMBH
Reel/Frame 063992/0870 →
Security Interest Oct 2, 2024
From: SECURA BIO, INC.
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 068774/0091 →